Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virus

Summary

Tissue factor (TF) is the blood coagulation initiator, whose cofactor function is required for physiological factor VIIa (FVIIa)-mediated activation of factor X (FX) to FXa. A previous study reported TF on herpes simplex virus type 1 (HSV1), but this explained only part of FVIIa-dependent FXa generation observed on the virus surface (Sutherland et al. (1997) Proc. Natl. Acad. Sci. USA. 94:13510-14). In the current study, we investigated the role of HSV1-encoded glycoprotein C (gC) in this process. Purified gC-deficient HSV1 facilitated several fold less FX activation by FVIIa than either wild type or gC-rescued strains.To confirm the implication of gC in FVIIa-dependent FX activation, purified soluble gC (sgC) enhanced FXa production in the absence of TF. sgC required FVIIa, calcium and anionic phospholipid to participate in FX activation, suggesting similarity to TF. When purified virus was combined with sgC, the sgC-dependent FXa generation was enhanced three orders of magnitude, suggesting synergy with an additional HSV1 component and explaining the relatively low activity of purified sgC compared to the viral counterpart. FX activation on gC-competent HSV1 was inhibited 20% by a gC-specific antibody, inhibited 40% by a TF-specific antibody, inhibited 65% by combining the gCand TF-specific antibodies, and nearly completely inhibited by the TF antibody alone on gC-deficient HSV-1. Cumulatively, these observations show that two pathways initiating FX activation function in parallel on the virus surface. In addition to the previously described TF-dependent pathway, HSV-1-encoded gC also enhances FXa generation, and like TF, requires FVIIa.

Keywords

Tissue factor - factor VII - factor X - glycoprotein C - herpes simplex virus

• References

• 1 Brown MS, Goldstein JL. Scavenging for receptors. Nature 1990; 343: 508-9.
• 2 Speir E, Modali R, Huang ES. et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994; 265: 391-4.
• 3 Sutherland MR, Raynor CM, Leenknegt H. et al. Coagulation initiated on herpesviruses. Proc Natl Acad Sci USA 1997; 94: 13510-14.
• 4 Pryzdial ELG, Wright JF. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid. Blood 1994; 84: 3749-57.
• 5 Bach R. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 1988; 23: 339-68.
• 6 Krishnaswamy S, Nesheim ME, Pryzdial ELG. et al. Assembly of the prothrombinase complex. Methods Enzymol 1994; 222: 260-280.
• 7 Tal-Singer R, Peng C, Ponce Mde Leon. et al. Interaction of herpes simplex virus glycoprotein gC with mammalian cell surface molecules. J Virol 1995; 69: 4471-83.
• 8 Friedman HM, Yee A, Cohen GH. et al. Glycoprotein C of herpes simplex virus type 1 acts as a receptor for the C3b complement component on infected cells. Nature 1984; 309: 633-5.
• 9 Harris SL, Frank I, Yee GH. et al. Glycoprotein gC of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Inf Dis 1990; 162: 331-7.
• 10 Friedman HM, Wang L, Fishman NO. et al. Immune evasion of herpes simplex virus type 1 glycoprotein gC. J Virol 1996; 70: 4253-60.
• 11 Etingin OR, Silverstein RL, Friedman HM. et al. Viral activation of the coagulation cascade: Molecular interaction at the surface of infected endothelial cells. Cell 1990; 61: 657-62.
• 12 Ruf W, Rehemtulla A, Edgington TS. Phospholipid-independent and -dependent interactions required for tissue factor receptor and cofactor function. J Biol Chem 1991; 266: 2158-66.
• 13 Krishnaswamy S, Field KA, Edgington TS. et al. Role of the membrane surface in the activation of human coagulation factor X. J Biol Chem 1992; 267: 26110-20.
• 14 Handler CG, Eisenberg RJ, Cohen GH. Oligomeric sturucture of glycoproteins in herpes simplex virus 1. J Virol 1996; 70: 6067-75.
• 15 Epstein SE, Speir E, Zhou YF. et al. The role of infection in restenosis and atherosclerosis: Focus on cytomegalovirus. Lancet 1996; 348: s13-s17.
• 16 Zhou YF, Leon MB, Waclawiw MA. et al. Association between prior cytomegalovirus infection and the risk of restinosis after coronary atherectomy. New Eng J Med 1996; 335: 624-30.
• 17 Nieto FJ, Adam E, Sorlie P. et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical restenosis. Circulation 1996; 94: 922-7.
• 18 Siscovick DS, Schwartz SM, Corey L. et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults - The Cardiovascular Health Study. Circulation 2000; 102: 2335-40.
• 19 Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A 1983; 80: 6386-9.
• 20 Cunningham MJ, Pasternak RC. The potential role of viruses in the pathogenesis of atherosclerosis. Circulation 1988; 77: 964-66.
• 21 Gyorkey F, Melnick JL, Guinn GA. et al. Herpesviridae in the endothelial and smooth muscle cells of the proximal aorta in arteriosclerotic patients. Exp Mol Pathol 1984; 40: 328-39.
• 22 Hendrix MG, Daemen M, Bruggeman CA. Cytomegalovirus nucleic acid distribution within the human vascular tree. Am J Pathol 1991; 138: 563-67.
• 23 Melnick JL, Petrie BL, Dreesman GR. et al. Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983; 02: 644-7.
• 24 Melnick JL, Schattner A. Viruses and Atherosclerosis. Isr J Med Sci 1992; 28: 463-5.
• 25 Gulizia JM, Kandolf R, Kendall TJ. et al. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol 1995; 147 (02) 461-75.
• 26 Fabricant CG, Fabricant J, Litrenta MM. et al. Virus induced atherosclerosis. J Exp Med 1978; 148: 335-40.
• 27 Fabricant CG, Fabricant J, Minick CR. et al. Herpesvirus induced atherosclerosis in chickens. Fed Proc 1983; 42: 2476-9.
• 28 Etingin OR, Silverstein RL, Hajjar DP. Identification of a monocyte receptor on herpesvirus-infected endothelial cells. Proc Natl Acad Sci USA 1991; 88: 7200-3.
• 29 van Dam-Mieras MCE, Muller AD, van Hinsbergh VWM. et al. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemostasis 1992; 68: 364-370.
• 30 Visser MR, Tracy PB, Vercellotti GM. et al. Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium. Proc Natl Acad Sci USA 1988; 85: 8227-30.
• 31 Vercellotti GM. Proinflammatory and procoagulant effects of herpes simplex infection on human endothelium. Blood Cells 1990; 16: 209-16.
• 32 Handler CG, Cohen GH, Eisenberg RJ. Crosslinking of glycoprotein oligomers during herpes simplex virus type 1 entry. J Virol 1996; 70: 6076-82.
• 33 Banner DW, D’Arcy A, Chene C. et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380: 41-6.
• 34 Lubinski J, Wang L, Mastellos D. et al. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein C. J Exp Med 1999; 190: 1637-46.
• 35 Fung LS, Neil G, Leibowitz J. et al. Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection. J Biol Chem 1991; 266: 1789-95.
• 36 Resnick-Roguel N, Eldor A, Burstein H. et al. The envelope glycoprotein of avian hemangioma retrovirus induces a thrombogenic surface on human and bovine endothelial cells. J Virology 1990; 64: 4029-32.
• 37 Neurath AR, Strick N. The putative cell receptors for hepatitis B virus (HBV), annexin V, and apolipoprotein H, bind to lipid components of HBV. Virology 1994; 204: 475-77.
• 38 Otto M, Gunther A, Fan H. et al. Identification of annexin 33 kDa in cultured cells as a binding protein of influenza viruses. FEBS Lett 1994; 356: 125-9.
• 39 Luan P, Yang L, Glaser M. Formation of membrane domains created during the budding of vesicular stomatitis virus: A model for selective lipid and protein sorting in biological membranes. Biochem 1995; 34: 9874-83.
• 40 Oie M. Reversible activation and reactivation of vaccinia virus by manipulation of viral lipid composition. Virology 1985; 142: 299-306.
• 41 Chejanovsky N, Zakai N, Amselem S. et al. Membrane vesicles containing the Sendai virus binding glycoprotein, but not the viral fusion protein, fuse with phosphatidylserine liposomes at low pH. Biochem 1986; 25: 4810-7.
• 42 Estepa A, Coll JM. Pepscan mapping and fusion-related properties of the major phophatidylserine-binding domain of the glycoprotein of viral hemorrhagic septicemia virus, a salmonid rhabdovirus. Virology 1996; 216: 60-70.
• 43 Mastromarino P, Cioe L, Rieti S. et al. Role of membrane phospholipids and glycolipids in the Vero cell surface receptor for rubella virus. Med Microbiol Immunol 1990; 179: 105-14.
• 44 Kuge O, Akamatsu Y, Nishijima M. Abortive infection with Sindbus virus of a Chinese hamster ovary cell mutant defective in phosphatidylserine and phosphatidylethanolamine biosynthesis. Biochem Biophys Acta 1989; 986: 61-9.
• 45 van Gendren IL, Brandimarti R, Torrisis MR. et al. The phospholipid composition of extracellular herpes simplex virions differs from that of the host cell nuclei. Virology 1994; 200: 831-6.
• 46 Braunagel SC, Summers md. Autographa californica nuclear polyhedrosis virus, PDV and ECV viral envelopes and nucleocapsids: structural proteins, antigens, lipid and fatty acid profiles. Virology 1994; 202: 315-28.